Roche Holding AG ADR Stock
€28.24
Your prediction
Roche Holding AG ADR Stock
Pros and Cons of Roche Holding AG ADR in the next few years
Pros
Cons
Performance of Roche Holding AG ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Roche Holding AG ADR | 1.010% | -1.199% | 0.099% | -22.665% | -13.578% | -18.180% | - |
Novartis AG ADR | 0.000% | 0.221% | 2.715% | -4.421% | -0.439% | 25.414% | 24.281% |
Bayer AG ADR | 6.620% | 3.571% | 7.407% | -49.301% | -15.698% | -45.489% | -52.303% |
Novo Nordisk A/S ADR | 0.860% | -2.110% | -0.429% | -21.886% | 23.667% | 88.312% | 173.585% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Roche Holding AG (RHHBY), a multinational healthcare company based in Switzerland, stands strong with its broad and diversified portfolio. A closer look into Roche's financial statements prominently reveals a robust business model underpinned by substantial revenues and a profitable margin.
Observing Roche's income statements over the past three years, the figures showcase an impressive gross profit with a steady upward trend. This consistency strongly indicates a robust operating model and proficient managerial efficiency. With increasing net income, the company seems to have experienced notable business and financial growth, reinforcing the credibility of the investment.
Roche also earns recognition for its significant investment in research and development, crucial for pharmaceutical companies. The data reveals a substantial annual expenditure, reflecting Roche's commitment to future growth and revolutionizing pharmaceutical breakthroughs, leading to a sustainable competitive advantage.
Comments
News
Why Roche Holdings Stock Popped Today
Shares of Swiss pharmaceuticals giant Roche Holdings (OTC: RHHBY) stock popped 2.5% in early trading Thursday before giving back about half of its gains.
Roche announced this morning that the U.S
This Big Pharma Is Teaming Up With Nvidia to Make Drugs With AI. Here's What You Need to Know
In late November, Roche's (OTC: RHHBY) subsidiary Genentech and the chipmaker Nvidia (NASDAQ: NVDA) agreed to collaborate on developing new medicines using artificial intelligence (AI) over the next